GHENT, Belgium, 9 January 2012 - Ablynx [Euronext Brussels: ABLX] today announced that it will present a review of its progress in 2011, together with an outline of the Company's evolving strategy and a review of its portfolio and priorities for 2012, at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, 9-12 January 2012.

During the course of 2011, Ablynx has made significant progress both commercially and clinically. Cash at the end of 2011 is expected to exceed EUR80M, including EUR12M of the EUR20M upfront fee from the third co-discovery and co-development deal with Merck Serono. During the year, four Phase II clinical trials of Nanobody®-based products were progressed or completed, with one achieving clinical proof-of-concept in a disease population. Five Phase I clinical trials were also further progressed or completed.

During 2012, Ablynx will focus its investments on its more advanced clinical assets, including ALX-0061 (anti-IL-6R) in rheumatoid arthritis (RA), ALX-0081/ALX-0681 (anti-vWF) in thrombotic thrombocytopenic purpura (TTP), ATN-103 (anti-TNF?) in RA, ALX-0171 (anti-RSV) in respiratory syncytial viral infections, and the co-discovery and co-development programmes with Merck Serono. The Company will continue to exploit the broad applicability of the Nanobody platform and it will seek partnerships for programmes to maximise potential value creation by accessing external resources and capabilities. Strong cash management will remain of key importance and the net cash burn target for 2012 is in the range of EUR20-25M.

The detailed presentation is available on Ablynx's corporate website under the section "Investors": www.ablynx.com/en/investors/overview/:
http://www.ablynx.com/en/investors/overview/. Edwin Moses, CEO and Chairman of Ablynx will give a presentation on Wednesday, 11 January 2012 at 03:30 p.m. PST / 00:30 a.m. CET. The live webcast may be accessed on Ablynx's homepage (www.ablynx.com:
http://www.ablynx.com/). Shortly thereafter, a replay of the webcast will be available on the Company's website for 30 days following the presentation.

For more information, please contact Ablynx:

Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com:
mailto:edwin.moses@ablynx.com

Marieke Vermeersch
Investor Relations Manager
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com :
mailto:marieke.vermeersch@ablynx.com%20

Complete version of the press release:
http://hugin.info/137912/R/1576150/491153.pdf


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Ablynx via Thomson Reuters ONE
HUG#1576150